HWAM
RYTM icon

Hennion & Walsh Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,908
Closed -$1.17M – 986
2025
Q4 		$1.17M Sell
10,908
-33,823
-76% -$3.59M 0.04% 486
2025
Q3 		$4.52M Sell
44,731
-6,348
-12% -$589K 0.16% 156
2025
Q2 		$3.23M Sell
51,079
-38,543
-43% -$2.36M 0.13% 199
2025
Q1 		$4.75M Sell
89,622
-9,825
-10% -$545K 0.21% 106
2024
Q4 		$5.57M Sell
99,447
-1,514
-1% -$83.6K 0.25% 84
2024
Q3 		$5.29M Buy
100,961
+4,583
+5% +$220K 0.25% 90
2024
Q2 		$3.96M Buy
96,378
+9,411
+11% +$376K 0.2% 119
2024
Q1 		$3.77M Buy
86,967
+20,259
+30% +$887K 0.2% 126
2023
Q4 		$3.07M Buy
66,708
+26,562
+66% +$838K 0.18% 160
2023
Q3 		$920K Buy
40,146
+18,963
+90% +$425K 0.06% 376
2023
Q2 		$349K Sell
21,183
-36,152
-63% -$653K 0.02% 610
2023
Q1 		$1.02M Sell
57,335
-1,963
-3% -$49.3K 0.06% 352
2022
Q4 		$1.73M Buy
59,298
+7,496
+14% +$193K 0.11% 227
2022
Q3 		$1.27M Sell
51,802
-717
-1% -$13.3K 0.08% 275
2022
Q2 		$218K Sell
52,519
-781
-1% -$4.28K 0.01% 709
2022
Q1 		$614K Buy
53,300
+1,088
+2% +$9.55K 0.03% 470
2021
Q4 		$521K Buy
52,212
+3,262
+7% +$36.6K 0.03% 532
2021
Q3 		$639K Buy
48,950
+16,757
+52% +$256K 0.03% 455
2021
Q2 		$630K Buy
32,193
+505
+2% +$10.5K 0.03% 473
2021
Q1 		$674K Buy
+31,688
New +$919K 0.04% 444

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Hennion & Walsh Asset Management's RYTM Position: Q1 2026 in Review

Hennion & Walsh Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 10,908 shares — an estimated $1.17M sold.

Hennion & Walsh Asset Management first reported a position in RYTM in Q1 2021 and held it in 20 quarters. The position peaked at $5.57M in Q4 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Hennion & Walsh Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 10,908 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $1.17M.
  • Hennion & Walsh Asset Management first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 20 quarters.
  • Hennion & Walsh Asset Management's Rhythm Pharmaceuticals position peaked at $5.57M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2026, filed 13 May 2026.